Abstract Genetic variants in MTHFD1 (5,10-methylenetetrahydrofolate dehydrogenase/5,10-methenyltetrahydrofolate cyclohydrolase/ 10-formyltetrahydrofolate synthetase), an important folate metabolic enzyme, are associated with a number of common diseases, including neural tube defects (NTDs). This study investigates the promoter of the human MTHFD1 gene in a bid to understand how this gene is controlled and regulated. Following a combination of in silico and molecular approaches, we report that MTHFD1 expression is controlled by a TATA-less, Initiator-less promoter and transcription is initiated at multiple start sites over a 126 bp region. We conWrmed the presence of three database polymorphisms (dbSNP) by direct sequencing of the upstream region (rs1076991 C > T, rs8010584 G > A, rs4243628 G > T), with a fourth (dbSNP rs746488 A > T) not found to be polymorphic in our population and no novel polymorphisms identiWed. We demonstrate that a common SNP rs1076991 C > T within the window of transcriptional initiation exerts a signiWcant eVect on promoter activity in vitro. We investigated this SNP as a potential risk factor for NTDs in a large homogenous Irish population and determined that it is not an independent risk factor, but, it does increase both case ( 2 = 11.06, P = 0.001) and maternal ( 2 = 6.68, P = 0.01) risk when allele frequencies were analysed in combination with the previously identiWed diseaseassociated p.R653Q (c.1958 G > A; dbSNP rs2236225) polymorphism. These results provide the Wrst insight into how MTHFD1 is regulated and further emphasise its importance during embryonic development.
Introduction
Folate, or vitamin B9, is an essential nutrient in our diet. Folate deWciency and polymorphisms within folate-dependent enzymes have been extensively associated with a number of common complex diseases and disorders, particularly, neural tube defects (NTDs). Non-syndromic NTDs are amongst the most common congenital disorders, occurring at an average rate of approximately 1 in 1,000 pregnancies per year (Busby et al. 2005) . The aetiology of NTDs is multifactorial, with both genetic and environmental factors, and the interaction between them playing a critical role. It is widely known and accepted that periconceptional folate supplementation can prevent up to 70% of all NTDs (MRC 1991; Czeizel and Dudas 1992) . The exact mechanism of this protective eVect is not completely understood but it is most likely by overcoming disruptions in folate metabolism, partially caused by underlying genetic variation in folate-related genes (van der Linden et al. 2006) .
One such genetic variant occurs in the gene for 5,10-methylenetetrahydrofolate (methyleneTHF) dehydrogenase; 5,10-methenylTHF cyclohydrolase; 10-formylTHF synthetase (MTHFD1; GenBank accession no. NM_005956.2). This gene encodes a 100 kDa nicotinamide adenine diphosphate (NADP+)-dependent trifunctional cytoplasmic enzyme that plays an important role in folate metabolism (Hum et al. 1988) . The enzyme consists of two functional domains; an amino-terminal portion (33 kDa) containing the dehydrogenase and cyclohydrolase activities, and a larger (67 kDa) synthetase domain in the carboxy-terminal region. MTHFD1 activity is essential for DNA synthesis, providing 10-formylTHF and 5,10-methyleneTHF for de novo purine and thymidylate synthesis. In addition to its enzymatic activity, biochemical evidence also suggests that MTHFD1 plays a role as a structural component in a multienzyme purine synthesising complex (Smith et al. 1980; Barlowe and Appling 1990) . Therefore, MTHFD1 is a vital enzyme, especially in rapidly dividing cells such as those of the developing embryo, where purines and pyrimidines are in constant demand for de novo DNA synthesis. A common single nucleotide polymorphism (SNP) at nucleotide 1,958 of the MTHFD1 gene causes a G to A transition, which results in an arginine to glutamate substitution at amino acid position 653 in the synthetase domain of the enzyme (dbSNP ID: rs2236225; Hol et al. 1998 ). This variant (usually referred to as R653Q) has been identiWed as a maternal risk factor for NTDs in the Irish population, with an excess of QQ homozygotes found in mothers of children with an NTD (Brody et al. 2002; Parle-McDermott et al. 2006) . Association with NTD risk was also reported in the Italian (De Marco et al. 2006) , but not in the Dutch, population (Hol et al. 1998; van der Linden et al. 2007 ). The R653Q polymorphism has also been identiWed as a risk factor for severe abruptio placentae and mid-trimester miscarriage in Irish mothers (Parle-McDermott et al. 2005a, b) , intrauterine growth restriction in Australian mothers (Furness et al. 2008 ) and congenital heart defects (CHD) in Canadian children (Christensen et al. 2008) ; although the association with CHD was not identiWed in a Chinese population (Cheng et al. 2005) . It has also been associated with increased risk for gastric cancer in a Chinese population (Wang et al. 2007) , as well as, increased risk for bipolar disorder and schizophrenia in a male Polish population (Kempisty et al. 2007) . Despite extensive evidence of its association with numerous common diseases, very little is known of the underlying functional eVect of this SNP. A recent study showed the polymorphism had no eVect on synthetase enzyme activity under normal assay conditions, but it was shown to aVect enzyme thermostability and to diminish its capacity for de novo purine synthesis (Christensen et al. 2008) . Although the coding region and 3Ј untranslated region (UTR) of the MTHFD1 gene have been investigated for novel polymorphisms (Parle-McDermott et al. 2006 ) the 5Ј region, including the promoter region had not been investigated prior to this study.
We sought to analyse the human MTHFD1 promoter by utilising both bioinformatics and experimental approaches to provide an understanding of the mechanisms responsible for regulation at the transcriptional level. Our investigation included a search for novel polymorphisms that may impact on gene expression and thus, could be related to the pathogenesis of a developmental defect, such as an NTD. We report here that MTHFD1 expression is controlled by a typical TATA-less, Initiator (Inr)-less promoter (Smale 1997) with transcription initiated at multiple start sites. A common SNP located within the window of transcriptional initiation signiWcantly aVects promoter activity in vitro. We found that this novel functional SNP is not an independent risk factor for NTDs in the Irish population, but it is signiWcantly associated with both case and maternal risk when analysed in combination with the R653Q (SNP rs2236225) polymorphism.
Materials and methods

Transcription start site identiWcation
Prediction of the transcription start site (TSS) was determined initially by utilising sequence databases such as DBTSS (http://dbtss.hgc.jp) and dbEST (www.ncbi.nih. gov/EST). The TSS was assessed experimentally using the First Choice ® 5Ј RLM-RACE kit (Ambion ® , UK were generated following PCR ampliWcation of 0.59 kb of the promoter region using genomic DNA from Coriell lymphoblast lines isolated from individuals that were homozygous for either allele. The sequences of these constructs were identical except for the polymorphism as veriWed by direct sequencing.
Reporter gene assays
FireXy luciferase reporter gene assays were carried out on transiently transfected human embryonic kidney (HEK) 293 cells. Cells were grown in DMEM (Dulbecco's modiWed eagle's medium) supplemented with 10% foetal calf serum, 1% penicillin/streptomycin (10,000 U: 10 mg/ml) and 1% L-glutamine (200 mM). Cells were seeded at a density of 1 £ 10 5 cells/ml, 24 h prior to transfection. An optimised concentration of 100 ng plasmid DNA was transfected using GeneJuice ® Transfection Reagent (Novagen, USA) and incubated for 24 h before assay. All cells were co-transfected with 40 ng Renilla luciferase plasmid (pRL-TK; Promega, UK) to normalise for transfection eYciency. Cells were lysed using passive lysis buVer (Promega, UK) and assayed for luminescence following incubation with either WreXy or Renilla luciferase substrate. Luminescence was measured using either a Mediators PhL (ImmTech Inc., New Windsor, MD, USA) or a Glomax™ (Promega, UK) luminometer. Each assay was performed in triplicate and each experiment was performed at least three times. All values were normalised to pRL-TK control values and expressed relative to empty pGL3 Basic values, with the mean, standard deviation and coeYcient of variation (CV) calculated.
Polymorphism screening
The putative regulatory region of MTHFD1 was screened for novel polymorphisms by designing six separate overlapping PCR assays of between 320 and 400 bp in size spanning 2 kb upstream of the translational start site. An assay to PCR amplify the Wrst 400 bp of Intron 1 was also designed. All primers sequences and optimised assay conditions are available in the Supplementary document. Genomic DNA from 22 Irish individuals was used as template for all PCR assays. The PCR products from each sample were cycle sequenced bi-directionally using Big Dye Terminator ® chemistry and the sequence traces were analysed for variations using the Seqman program, as part of the DNASTAR, Lasergene ® suite. Haplotype block analysis was performed using the default algorithm of Haploview, version 3.2 (www.broad.mit.edu/personal/jcbarret/haploview).
Genotyping of SNP rs1076991
Genotyping of SNP rs1076991 was carried out by matrix assisted laser desorption ionisation-time-of-Xight (MALDI-TOF) mass spectrometry of primer extension products using the Homogenous MassEXTEND ® Assay (hME ® ; Sequenom ® , CA, USA). The following primers were used to amplify an 89 bp PCR product containing the SNP: forward [5Ј ACGTTGGATGGGCGCAGGCGCAGTAGTGT 3Ј] and reverse [5Ј ACGTTGGATGAGCCAAGCAG GACAACCCAA 3Ј]. An extension primer [5Ј GCAGTA GTGTGATCCCC 3Ј] was designed to anneal directly adjacent to the SNP site. Genotypes were called using SpectroTYPER ® software. A PCR-restriction fragment length polymorphism (RFLP) method was also used to re-genotype > 10% of DNA samples in an external quality control assay. A 334 bp region surrounding the SNP was ampliWed by PCR and the product was digested with Msp I (20U) restriction enzyme, resulting in a 233 and a 99 bp product in the presence of the C allele.
Study population
Families aVected by an NTD pregnancy were recruited throughout the Republic of Ireland with the assistance of the Irish Association for Spina BiWda and Hydrocephalus (IAS-BAH) and the Irish Public Health Nurses from 1993 to 2005. These families (n = 594), consisting of both complete and incomplete triads (case, mother, father), formed the NTD cohort. Genotype information for MTHFD1 SNP rs2236225 was available for the majority of these samples from the previous studies (Brody et al. 2002; Parle-McDermott et al. 2006 ).
Blood samples were obtained from a population of 56,049 pregnant women attending the three main maternity hospitals in the Dublin area between 1986 and 1990 (Kirke et al. 1993) . The control group (n = 999) was randomly selected from those women who did not have an NTDaVected pregnancy and had no previous NTD history. An additional control group (n = 216) from the same collection was also included as data relating to red cell folate (RCF) and homocysteine levels were available for these samples. Informed consent and ethical approval was obtained for all human samples used in this study.
Statistical analyses
DiVerences in activity of the promoter constructs were assessed using a two-tailed, unpaired Student's t test. A 2 test was used to compare allele frequencies between NTD triad and control groups. A homozygous TT genotype eVect was investigated by calculation of an odds ratio (OR) with 95% conWdence intervals. OR is computed as the ratio of carriers to non-carriers in cases compared with controls and, thereby, estimates the risk conferred by the particular genotype. Log-linear analysis Wilcox et al. 1998 ) was performed using the SAS PROC GEN-MOD program. This uses a likelihood ratio test to examine the joint transmission of alleles from parents to the aVected oVspring, which enables detection of indirect genetic inXuence, i.e., the maternal genotype and interactive genotype eVects. A TDT analysis was also performed on informative triads, i.e., those with at least one heterozygous parent, to investigate any deviation in normal allele segregation from parents to aVected child. Complete triads were analysed using the TDT/STDT program Version 1.1, which has a 2 distribution with 1 df. SNP-SNP interactions in NTD mothers and cases were assessed by logistic regression using SAS PROC GENMOD software. The OR for combined genotype or allele frequencies of both SNPs was estimated to assess a possible increased risk due to having a speciWc combination of alleles and/or genotypes in cases or mothers compared with controls. A complementary test for interaction was performed utilising log-linear modelling and employed all members of the triad data rather than comparing each group to controls. These approaches for detecting SNP-SNP interactions allows for testing combined eVects on risk and are not biased towards previously established independent SNP eVects. SigniWcance was set at P < 0.05 for all statistical testing.
Results
TSS identiWcation
A multisite pattern of transcriptional initiation was predicted in silico and then experimentally conWrmed using the 5Ј RLM-RACE method. At least 28 diVerent TSSs were experimentally identiWed in a region spanning from ¡30 to ¡156 bp, relative to the ATG start codon ( Supplementary  Fig. 1 ). Within this 126 bp window of initiation three TSSs, at positions ¡68, ¡72, and ¡100, were used most frequently and have been designated as the major TSSs of the MTHFD1 gene. An alternate upstream exon was not identiWed and there were no signiWcantly diVerent patterns of transcriptional initiation between individuals or between lymphocytes and placental cells. Interrogation of the EST database (dbEST) conWrmed the absence of an alternative upstream exon and the lack of a deWnitive TSS (Supplementary Fig 2) .
Bioinformatics and reporter gene assays deWne the MTHFD1 promoter region
In silico analysis revealed that the MTHFD1 promoter is both TATA-less and Inr-less. Regions of regulatory importance are indicated by the presence of a 1.38 kb CpG island spanning a region from 1 kb upstream extending into Intron 1. Numerous putative TF binding sites were identiWed within the upstream region; far too many to all have biological relevance. Therefore, comparison to previously characterised promoters of similar folate-related/TATA-less genes was employed to identify those likely to be functional. Putative Sp1, E2F, and NRF-1 TF binding sites were identiWed, as well as, a consensus E-box (CACGTG) that is conserved across human, rat and mouse species (Fig. 1) . Experimental investigation of promoter activity revealed signiWcant levels of transcriptional activity in constructs ranging from 0.26 to 2 kb upstream of the ATG start codon (Fig. 2) . A construct of 0.59 kb displayed the highest level of activity but was similar to the 0.47 kb and 1 kb constructs. Promoter activity was reduced to basal levels in a 0.11 kb construct, demonstrating that the region most important for activated MTHFD1 gene transcription occurs between 0.11 and 0.47 kb upstream. The 1.94 kb construct showed a drop in luciferase activity, possibly due to the presence of a repressor element. The mean intra-assay CV for these experiments was 10.2% and the mean inter-assay CV was 9.6%.
Polymorphism screen A sequencing screen of the MTHFD1 regulatory region, spanning from 2 kb upstream of the translational start site to the Wrst 400 bp of Intron 1, was performed with no novel polymorphisms identiWed. Three dbSNP-listed SNPs were identiWed in the upstream region: ¡105 C > T (rs1076991), ¡1,470 G > A (rs8010584), and ¡1,474 G > T (rs4243628). A fourth SNP present in dbSNP (¡473 A > T; rs746488) was not identiWed in our screen, suggesting this SNP is either a rare variant and was not detected in this small screen, or it is not variable in the Irish population. Haplotype analysis revealed that all three identiWed SNPs are in LD with each other in the same haplotype block. SNP rs1076991 and rs8010584 are in complete LD (DЈ = 1; R 2 = 0.76) and SNP rs4243628 is in strong LD with both (DЈ = 0.87; R 2 = 0.51 and DЈ = 0.79; R 2 = 0.48, respectively). These SNPs are not in LD with SNP rs2236225 (DЈ = 0.2; R 2 = 0.01). Common haplotypes for the three upstream SNPs in this population are: GGC = 0.41; TAT = 0.4; GAT = 0.1. Fig. 1 Sequence analysis of the MTHFD1 promoter region. A CpG island spans the promoter region and is shown underlined. Putative transcription factor binding sites in the MTHFD1 upstream region were identiWed using MatInspector and AliBaba2 programs. Those likely to have biological function are shown surrounded by boxes and their direction indicated by arrows. A consensus E-box that is conserved in human, rat and mouse is illustrated by a shaded box. Database SNPs (rs1076991 C > T and rs746488 A > T) are also highlighted in bold capitals. Two additional database SNPs (rs8010584 G > A and rs4243628 G > T) are located further upstream and are not shown here Fig. 2 Relative luciferase activity of a series of MTHFD1 promoter constructs. MTHFD1 promoter constructs ranging in size from 0.11 to 1.94 kb were assayed for their ability to drive transcription in a luciferase reporter gene system. The ¡1 in the MTHFD1 upstream region refers to the nucleotide immediately upstream of the translational start site. The 0.59 kb construct was found to induce the highest levels of luciferase activity, but was similar to the activity of the 1 kb and 0.47 kb constructs. A lower level of promoter activity was associated with the larger 1.94 kb construct while the promoter activity was almost abolished with the 0.11 kb construct. Results are expressed relative to empty vector values and as the percentage mean activity of at least three separate experiments performed in triplicate Functional characterisation of SNP rs1076991
The presence of the common SNP rs1076991 C > T in the window of transcriptional initiation has a signiWcant eVect on MTHFD1 promoter activity in vitro, with the 'T' 0.59 kb promoter construct only 38% as transcriptionally active as the 'C' 0.59 kb promoter construct in a luciferase reporter gene assay (P = 0.04; Fig. 3 ). No other sequence variation was present between the two constructs, since both contained the more common allele for SNP rs746488 while SNPs rs8010584 and rs4243628 are localised 5Ј to the 0.59 kb construct.
The existence of a biochemical phenotype for SNP rs1076991 was investigated following genotyping of a control group, by correlating rs1076991 genotype with RCF and homocysteine levels. A signiWcant diVerence in RCF and/or homocysteine levels was not observed between diVerent genotype groups. Mean RCF levels (ng/ml) with 95% conWdence interval for the CC, CT, and TT genotypes were: 349 [302-389], 324 [295-347] , and 316 , respectively, which are not signiWcantly diVerent (P = 0.54). Mean homocysteine levels were 7.57 [7.0-8.2], 8.07 [7.6-8.6], and 7.69 [7.2-8.2] for the CC, CT, and TT genotypes, respectively, which again are not signiWcantly diVerent (P = 0.34).
Genotyping of SNP rs1076991 and association with NTDs
A total of 2,462/2,561 (96%) DNA samples were genotyped successfully using the mass spectrometry-based assays. Of these samples, 284 were re-genotyped as a quality control measure, with a 94% agreement rate. A further 277 samples were re-genotyped in an external quality control assay and the rate of agreement was 96%. Genotype and allele frequencies for SNP rs1076991 in each of the study groups are displayed in Table 1 .
Case/control analysis revealed that SNP rs1076991 is not associated with NTD risk in the Irish population, since there is no signiWcant diVerence in genotype/allele frequencies between NTD family groups and the control group (Table 1) . Likewise, log-linear analysis did not reveal any risk association with case genotype ( 2 = 0.23, P = 0.89), with maternal genotype ( 2 = 4.53, P = 0.1), or with casematernal interaction ( 2 = 0.86, P = 0.86). A TDT analysis was carried out on complete triads (n = 353). A total of 359 informative genotypes, i.e., heterozygous parents, were identiWed and transmission analysed. No preferential transmission of either allele was observed [C = 185 (52%), T = 174 (48%), 2 = 0.34, P = 0.53]. A potential SNP-SNP interaction between SNP rs1076991 and SNP rs2236225 in relation to NTD risk was also investigated. Two-locus genotype frequencies for SNP rs1076991 and SNP rs2236225 were calculated for NTD family groups and controls ( Table 2) . Comparison of Fig. 3 Relative activity of diVerent SNP rs1076991 genotype promoter constructs. A total of three luciferase reporter gene assays, each with a fresh preparation of 0.59 kb promoter clones, were performed to investigate the eVect of SNP rs1076991 on promoter function. No other polymorphic variants were present within this region; therefore, any eVect is solely due to SNP rs1076991. The overall result is expressed as the mean and SD of fold luciferase activity (FireXy/Renilla) detected in each construct above the empty vector (pGL3basic). The 'T' construct exhibited an approximately 1.6-fold (or 62.5%) drop in activity relative to the 'C' construct. This diVerence was shown to be statistically signiWcant, with P = 0.04 using a two-tailed Student's unpaired t test Values might not add to 1 due to rounding b OR odds ratio; LL lower limit, UL upper limit combined allele frequencies revealed an interaction in both the case group ( 2 = 11.06, P = 0.001) and the maternal group ( 2 = 6.68, P = 0.01). Analysis of genotype combinations revealed that both NTD cases (0.11) and mothers (0.11) have a higher frequency of the rs1076991 TT/ rs2236225 AA genotype compared to controls (0.05). Logistic regression analysis of these genotype combinations revealed a signiWcant interaction between SNP rs1076991 and SNP rs2236225 in cases ( 2 = 20.15, P = 0.001) but not in mothers ( 2 = 7.01, P = 0.14). Maternal and case genotype interactive eVects were also tested using the triad data only. This analysis complements the maternal/cases versus control analyses but has less power due to incomplete triads. Statistical signiWcance was not reached for maternal (P = 0.10) or case genotype interactions (P = 0.36).
Discussion
MTHFD1 is a logical candidate gene for investigation in relation to disease risk; thus, we have undertaken the primary study of the promoter controlling its expression, and report the existence of a functional promoter SNP, rs1076991 C > T, which aVects gene expression in vitro. Our results demonstrate that the MTHFD1 gene is regulated by a TATA-less, Inr-less promoter that directs transcriptional initiation at multiple start sites within a 126 bp initiation window in the upstream region. Three major TSSs were identiWed at positions 68, 72 and 100 bp upstream of the translation start site. An alternate upstream exon is not present and TSS usage is similar between diVerent individuals and tissue types investigated (lymphocyte and placenta). This type of TATA-less promoter with multiple start sites resembles that found in other folate-related genes, including thymidylate synthase (Dong et al. 2000) and reduced folate carrier (Gong et al. 1999) , and is also similar to the promoter controlling rat Mthfd1 expression (Howard et al. 2003) . A 1.38 kb CpG island spans the promoter region, and is associated with the presence of multiple GC boxes, suggesting that Sp1 is an important TF for gene regulation (Brandeis et al. 1994) . It has been proposed that these Sp1 sites may serve to maintain the hypomethylated state of such promoters, indicating that the gene will be constitutively expressed (Pugh and Tjian 1990) . In silico prediction and previously reported empirical evidence from large-scale promoter studies suggest the E2F family of TFs will also play an important role in MTHFD1 gene expression (Cam et al. 2004; Weinmann et al. 2002) . Therefore, it is likely that MTHFD1 will be cell cycle-regulated and, although predicted to be constitutively expressed, an upregulation of its expression during S phase would be expected given its role in DNA synthesis, followed by a down-regulation in the G 0 and G 1 phases. In silico analysis also indicates that c-Myc-Max binding to a conserved E-box motif regulates MTHFD1 expression. Cross-species conservation signiWes the importance of this promoter feature, since nucleotide sequences that are actively conserved during evolution are likely to be of biological importance. Evidence of functionality is also supported by identiWcation of cMyc-Max binding to the MTHFD1 upstream region in another large-scale promoter binding study (Mao et al. 2003) . The c-Myc TF can play a role in recruiting factors necessary for the initiation of transcription to the core promoter (Hermann et al. 2001; McEwan et al. 1996) and could be responsible for this process in the absence of a TATA box/Inr in the MTHFD1 promoter. Co-ordinated binding of these TFs, as well as other predicted ones such as NRF-1, is likely responsible for the high levels of activated transcription measured from the MTHFD1 promoter, especially within the Wrst 0.47 kb of the upstream region, which supports the highest level of transcriptional activity. Activated transcription was not induced by a promoter construct of 0.11 kb, demonstrating the absence of essential regulatory elements and indicating that the minimal promoter region for activated transcription of this gene is between 0.11 and 0.26 kb upstream. The drop in activity observed in the 1.94 kb construct may be due to a yet to be identiWed repressor element. Our analysis was conWned to the 2 kb region upstream of the translational start site of MTHFD1; thus, we cannot rule out the role of additional regulatory elements further upstream of this. Promoter function and normal gene expression can be signiWcantly aVected by polymorphisms in important regulatory regions (Hoogendoorn et al. 2003) . SNP rs1076991 C > T is located within the window of initiation and was shown to have a signiWcant impact on promoter function in vitro. Transcriptional activity of the 0.59 kb 'T' promoter construct was shown to be about 1.6-fold less than that of the 0.59 kb wildtype 'C' construct. If this eVect is translated in vivo, a decrease in MTHFD1 gene expression could result in lower levels of the MTHFD1 enzyme available for purine and thymidylate synthesis; a situation that could be detrimental under certain conditions, especially during times of increased demand on de novo DNA synthesis, such as embryogenesis. However, results obtained from in vitro reporter gene studies should be interpreted with caution, since gene regulation and expression in the natural genomic environment in vivo is undoubtedly more complex than seen in the cell line model. Bioinformatic analysis did not reveal an alteration of any consensus TF binding site that would explain the observed diVerence in activity between the two genotypes. The loss of a DNA methylation site is also possible, but is unlikely to explain the reduced expression of MTHFD1 in vitro. The most likely explanation for the functional impact of SNP rs1076991 on MTHFD1 gene expression is through the loss or gain of binding to a non-consensus binding site, the identiWcation of which would require further investigation.
Polymorphisms that exert a functional eVect, such as SNP rs1076991, are those most likely to be involved in common disease. The link between disruptions to folate metabolism and NTD risk is well established and, more speciWcally, variation in the MTHFD1 folate enzyme has previously been associated with NTD risk in the Irish population (Brody et al. 2002; Parle-McDermott et al. 2006) . Therefore, SNP rs1076991 was investigated as a candidate polymorphism for NTD risk in the Irish population in a large association study using both case/control and family triad-based analysis methods. SNP rs1076991 was not associated with NTD risk/protection in this study, nor did it have an eVect on RCF or homocysteine levels analysed in a separate control group. However, SNP-SNP interaction analysis with MTHFD1 SNP rs2236225 (R653Q) revealed a highly signiWcant association with NTD risk in both case (genotype and allele frequencies) and maternal groups (allele frequencies only). These two SNPs are not in LD with each other and, therefore, the identiWed interaction cannot be attributed to simple co-segregation. Therefore, it seems that the SNP rs1076991, while not an independent risk factor for NTDs, in some way contributes to the risk associated with SNP rs2236225 and homozygosity for these two SNPs confers a greater risk than either one in isolation. SNP-SNP interaction is particularly relevant in the aetiology of common complex diseases, where it is likely that the mechanism of action of one variant may be inXuenced by the presence or absence of another. Further investigations of SNP-SNP interaction in relation to abruptio placentae, mid-trimester miscarriage risk, and would be of particular interest, since the rs2236225 AA genotype is a known risk factor (Parle-McDermott et al. 2005a, b) for both these conditions and it is possible that the presence of SNP rs1076991 confers an even greater risk. However, we do acknowledge the limitations of our data set and conWrmation of this interaction in a second NTD cohort would be desirable.
We are the Wrst to investigate the promoter of MTHFD1 and to identify a novel functional SNP rs1076991 that may have disease relevance. The results reported here marks a step in the direction toward understanding the underlying molecular pathways and disruptions involved in folaterelated disease development and progression. This is necessary to achieve the fundamental goal of elucidating the aetiology of these complex diseases and, eventually, optimising individual folate status to prevent or overcome them.
